Frances Martin, MD , is an Associate Professor in the Department of Urology at the University of Kentucky. She is a member of the Markey Cancer Center and the Translational Oncology Research Program, focusing on prostate and bladder cancer research, particularly active surveillance, biopsy techniques, and dietary influences on cancer progression. Education : Bachelor of Science (1992) from Vanderbilt University Master of Science (1997) from University of South Alabama Doctor of Medicine (2003) from University of Alabama School of Medicine Postdoctoral Fellowship at University of Texas M.D. Anderson Cancer Center (2010) Her research spans prostate cancer (Gleason Score analysis, genetic predisposition, biochemical recurrence) and bladder cancer (neoadjuvant chemotherapy, histologic subtypes). Recent publications analyze dietary patterns, germline mutations, and active surveillance outcomes. Collaborations include institutions like JAMA and Cancer Medicine journals, with 12 research outputs and 7 h-index citations from Scopus.
Paula Videira serves as Associate Professor at NOVA University Lisbon's Faculty of Science and Technology (FCT-NOVA) and leads the Glycoimmunology Group at the UCIBIO research unit. With expertise spanning Glycobiology, Immunology, and Oncology, she directs a highly productive research program focused on understanding glycan expression mechanisms and their impact on human disease. Her research centers on three interconnected themes: 1) mechanisms behind aberrant sialylated short O-glycans in cancers and their implications for tumor immunity; 2) the role of sialylated glycans in immunomodulatory molecule expression; and 3) how Congenital Defects of Glycosylation (CDG) affect immune responses and infection susceptibility. Dr. Videira employs cutting-edge methodologies including in vitro and in vivo assays, omics technologies , bioinformatics tools , and patient-centric approaches to translate discoveries into clinical applications. Analysis of her recent publications reveals a consistent focus on glycan-cancer interactions , particularly examining sialyl-Tn and related structures as biomarkers and therapeutic targets. Her work spans bladder cancer, breast cancer, and CDG research, with increasing emphasis on clinical translation through monoclonal antibody development and diagnostic tools. 101 peer-reviewed publications in top journals (BBA, Molecular Oncology) 4 patents as principal investigator 11 invited reviews including highly cited CDG therapy review Nearly 4.5 million EUR secured in research funding Additional 1.4 million EUR for technology spin-off Dr. Videira actively mentors PhD and Master's students while leading international collaborations. She co-founded CDG&Allies-PPAIN , a patient-centric network with nearly 100 professionals worldwide, and CellmAbs (2019), a biopharmaceutical company developing immuno-oncology agents that was recognized among the top 30 biotech startups by Biotecnika. Her leadership extends to editorial boards (Scientific Reports), international advisory roles (Slovak Academy of Sciences), and organization of international glycoscience courses and workshops.
Stacey Kenfield, ScD, is a faculty member at the University of California San Francisco (UCSF), affiliated with the School of Medicine and the Department of Epidemiology and Biostatistics. She is a leading researcher in cancer epidemiology, with a focus on prostate cancer, lifestyle interventions, and survivorship. As Principal Investigator on multiple NIH-funded studies, she has advanced understanding of how diet, exercise, and behavior influence cancer outcomes. Education: BS, Physiological Science, UCLA, 2000 MS, Epidemiology, Harvard School of Public Health, 2003 ScD, Epidemiology, Harvard School of Public Health, 2006 Dr. Kenfield's research centers on nutritional epidemiology, exercise oncology, and behavioral health in cancer survivors. Her work explores how plant-based diets, physical activity, sleep, and mHealth interventions impact prostate cancer progression, quality of life, and survival. She emphasizes health equity and community engagement, particularly in diverse and underserved populations. Her recent publications reveal a strong trend in lifestyle-based interventions for cancer survivors, with a focus on modifiable risk factors such as diet, physical activity, and sleep. The studies span clinical trials, cohort analyses, and meta-reviews, often incorporating patient-reported outcomes and genomic or microbiome data to understand mechanisms. Collaboration is central to her research, with frequent co-authorship across UCSF and national institutions. Scientific Awards: Harvard School of Public Health Teaching Assistant Award Association of Schools of Public Health and Legacy Foundation STEP-UP Award Fellowship (pre-doctoral) NIH Research and Career Development Award in Nutritional Epidemiology of Cancer (pre- and post-doctoral) American Association for Cancer Research Minority Scholar in Cancer Research Award Michael Milken Prostate Cancer Foundation Young Investigator Award Dr. Kenfield has led major NIH-funded grants including R01CA207749 on web-based lifestyle interventions in prostate cancer and R21CA184605 on exercise for men with metastatic prostate cancer. She mentors junior researchers and collaborates widely on studies involving behavioral interventions, cancer survivorship, and health disparities. While specific advisees are not listed, her leadership in large trials suggests active mentorship. Her work continues to inform clinical guidelines and public health strategies for cancer survivors. She is actively involved in multi-institutional research teams such as the INTERVAL-GAP4 Trial and the EMOVES study, which focus on physical activity and community-engaged lifestyle interventions. These teams include experts in oncology, epidemiology, urology, and behavioral science, reflecting the interdisciplinary nature of her research.
Bernard Bochner is a Professor of Urology at Memorial Sloan Kettering Cancer Center (MSK), where he serves as an Attending Physician in the Department of Surgery. He is affiliated with the Genitourinary Oncology Service and Solid Tumor Oncology Division, with extensive contributions to urologic oncology research. Dr. Bochner's research focuses on urologic oncology, particularly bladder cancer, genitourinary malignancies, and surgical oncology. His work spans cancer staging, treatment response, surgical complications, and survivorship issues. He has made significant contributions to understanding treatment resistance in bladder cancer, surgical outcomes following radical cystectomy, and the impact of tumor biology on clinical outcomes. His publication record shows a strong emphasis on clinical and translational research in genitourinary cancers, with numerous high-impact papers in journals like European Urology, Journal of Clinical Oncology, and Journal of Urology. His recent work addresses critical issues in bladder cancer management, surgical techniques, and improving quality of life for cancer survivors. Dr. Bochner has collaborated extensively with leading researchers at MSK, including Guido Dalbagni, Hikmat Al-Ahmadie, and Dean Bajorin, contributing to over 470 publications including 260 journal articles and 157 meeting abstracts. As an active researcher and clinician, Dr. Bochner continues to advance the field of urologic oncology through rigorous clinical investigation and innovative approaches to cancer care.
Dr. Laura Grocutt serves as an Honorary Research Fellow within the School of Cancer Sciences at the University of Glasgow, conducting research at the Radiotherapy Physics division of the Beatson West of Scotland Cancer Centre in Glasgow. Her research program focuses on optimizing radiation therapy through adaptive protocols, dose escalation, and hypofractionation techniques for bladder, rectal, and oropharyngeal cancers. She investigates clinical feasibility of advanced radiotherapy regimens while addressing systemic challenges like pandemic-induced service disruptions, aiming to enhance treatment precision and healthcare resilience. Analysis of her 2022-2024 publications reveals consistent emphasis on translating technical innovations into clinical practice across multiple cancer sites, with strong collaboration between the Beatson Centre and University of Glasgow researchers. No scientific awards are documented in available sources. While her work involves interdisciplinary teams at the Beatson Cancer Centre, details regarding student supervision, grant funding, or laboratory structure remain unspecified in source materials.
Gottfrid Sjödahl is an Associate Professor and Researcher at Lund University Cancer Centre (LUCC), where he leads the Urothelial Cancer Genomics research group. His work bridges clinical urology and molecular oncology, focusing on bladder cancer subtyping and therapeutic innovation. Research interests include: Molecular taxonomy of urothelial cancers Genomic drivers of bladder cancer progression Tumor microenvironment dynamics Immunotherapy response biomarkers Cost-effectiveness of precision oncology approaches His recent publications demonstrate a strong focus on molecular classification systems (LundTax algorithm), tumor plasticity studies across microenvironments, and immune profiling of bladder cancer subtypes. This work integrates computational biology, clinical oncology, and translational research. Active research projects: Principal Investigator: Molecular subtype-dependent biomarkers for systemic treatment of advanced bladder cancer (Cancerfonden, 2023-2025) Co-supervisor: Cellular and molecular cartography of muscle-invasive bladder cancer (Doctoral project, 2019-2025) He contributes to LUCC's urothelial cancer research initiatives and participates in academic events including cancer genomics seminars and research dissemination activities.
Matthew G. Kaag, MD, is an Associate Professor in the Department of Urology and Department of Surgery at Penn State University. His research focuses on bladder cancer, transitional cell carcinoma, and urological oncology, with a particular emphasis on muscle-invasive bladder cancer, patient perspectives, and clinical management strategies. He has contributed to studies on diagnosis stage optimization, immunotherapy in localized urothelial cancer, and complications arising from prostate biopsy procedures. Primary Affiliation: Penn State University (Department of Urology and Department of Surgery) Dr. Kaag’s work aligns with global health priorities, particularly in cancer control and treatment. His recent publications highlight trends in bladder cancer research , urothelial cancer , and healthcare access disparities . Notable collaborations include studies on durvalumab-based immunotherapy (Journal for ImmunoTherapy of Cancer, 2023) and systemic analysis of bleeding complications post-biopsy (Urology Practice, 2023).
Alejandro Sanchez, MD, is an Assistant Professor at the University of Utah School of Medicine and a Huntsman Cancer Institute investigator. He specializes in surgical care for urologic cancers using advanced techniques and focuses on clinical trial development and translational research in renal and prostate cancers. Dr. Sanchez earned his undergraduate degree in Biochemistry from the University of Florida (Summa Cum Laude), a medical degree from Harvard Medical School, and completed residencies/fellowships at Massachusetts General Hospital and Memorial Sloan Kettering Cancer Center, where he received the Young Investigator Award and Chairman’s Award for Excellence in Basic Science. His research explores the interplay between body composition (e.g., sarcopenia, visceral fat) and oncologic outcomes, particularly in clear cell renal cell carcinoma. He also investigates immunotherapy, clinical trials, and genomic factors in urinary tract cancers. Recent work includes trials like NEXT (nivolumab adjuvant therapy) and RadSABR (radiation for prostate cancer). Key awards include the Young Investigator Award and Chairman’s Award for Excellence in Basic Science. Scientific Awards: Young Investigator Award (American Society of Urologic Oncology) Chairman’s Award for Excellence in Basic Science Dr. Sanchez’s clinical practice addresses prostate, bladder, kidney, testicular, adrenal, urethral, and penile cancers. He has contributed to over 30 publications, with a focus on prognostic markers, cancer genomics, and obesity paradox studies.
Louis de Weerd is a Professor at the Department of Clinical Medicine, UiT The Arctic University of Norway, specializing in plastic and reconstructive surgery with a focus on cold weather injuries and advanced imaging techniques. Institution: UiT The Arctic University of Norway Department: Department of Clinical Medicine Email: louis.d.weerd@uit.no His research integrates dynamic infrared thermography and indocyanine green fluorescence angiography to optimize flap perfusion in complex reconstructive procedures. He has pioneered techniques for frostbite sequelae treatment , vesicovaginal fistula closure , and lipedema surgical management , addressing gaps in circumpolar health and postoperative care. He actively collaborates with multidisciplinary teams in the Dermatoplastic Imaging Research Group , contributing to advancements in perforator flap surgery and dead space obliteration . His work extends to clinical education and international partnerships, particularly in circumpolar and tropical surgical contexts. Recent publications highlight his expertise in muscle flap applications , free fibula grafts , and innovative imaging protocols , with a focus on improving outcomes for patients with complex surgical needs.
Meenakshi Anurag is an Assistant Professor in the Department of Medicine at Baylor College of Medicine, Houston, TX, where she leads a research program focused on precision oncology through bioinformatics and multi-omics data science. Her work targets cancer heterogeneity, particularly in breast cancer subtypes including rare male breast cancer, to improve diagnosis, treatment selection, and survival outcomes. Education: PhD in Bioinformatics, Institute of Genomics & Integrative Biology, New Delhi, India (2014) Postdoctoral Fellowship, Baylor College of Medicine, Houston Her research centers on cancer multi-omics analysis , immune informatics , and breast cancer therapeutics. Using next-generation sequencing and proteomics, she investigates molecular drivers of therapeutic resistance, notably identifying DNA damage repair defects as endocrine therapy resistance mechanisms in ER+ breast cancer. Current work explores immune-checkpoint factors in treatment-refractory disease through integration of genomic, transcriptomic, and metabolomic data with clinical profiles. Analysis of her 2024-2025 publications reveals dominant themes in proteogenomics of breast cancer (ER+, HER2+, TNBC), bladder cancer, and lung adenocarcinoma. Key trends include biomarker discovery for therapy resistance, computational deconvolution of chemotherapy responses using patient-derived xenografts, and identification of novel molecular vulnerabilities like NF1 depletion and LIG1 deficiency. Her work emphasizes translating multi-omics insights into clinical applications for precision oncology. Dr. Anurag conducts research at the BCM-Jewish Institute for Research (Lab), Room 645D, Houston, TX 77030, with technical expertise spanning NGS analysis, cancer genomics, and immune-informatics.
Jennifer K Yates serves as Associate Professor in the Department of Urology at UMass Chan Medical School and the T.H. Chan School of Medicine. Her academic career spans clinical practice, research, and medical education within the urological sciences field. Education: BA in Biology & Psychology from St. Mary's College of Maryland, St. Marys City, MD MD from Saint Louis University School of Medicine, Saint Louis, MO Dr. Yates' research primarily focuses on urological oncology with particular expertise in kidney neoplasms, urothelial carcinoma, and renal cell carcinoma. Her work bridges clinical practice with molecular diagnostics, exploring innovative approaches to cancer detection and treatment. She has made significant contributions to understanding Lynch syndrome-associated urothelial cancers and complications in urological procedures. Her publication record demonstrates consistent productivity since 2016, with increasing focus on workforce issues in urology, cancer genomics, and geriatric surgical outcomes. Recent publications highlight her engagement with contemporary challenges in urological practice, including gender diversity in the specialty and innovative diagnostic techniques. Dr. Yates collaborates extensively with colleagues across disciplines including pathology, radiology, geriatrics, and transplantation surgery. Her co-author network includes Mitchell Sokoloff, Alok Kapoor, Andrew Fischer, and Kriti Mittal, reflecting interdisciplinary approaches to urological research. Within the UMass Chan Medical School Department of Urology, Dr. Yates works alongside colleagues including Ashley Alford, Paula Bellin, Jennifer Fantasia, Mitchell Sokoloff, and Stephen Tosi. Her research contributes to the department's reputation in urological oncology and clinical innovation.
Hooman Djaladat, MD, is a Professor of Clinical Urology at the Keck School of Medicine of the University of Southern California (USC). He specializes in urologic oncology, endourology, and minimally invasive urology, with a focus on complex urologic cancers, robotic surgery, and surgical outcomes research. Dr. Djaladat's academic career includes roles as a faculty member since 2004, with a particular emphasis on upper tract urothelial carcinoma and bladder cancer management. He completed his medical training at Tehran University of Medical Sciences and a urology residency at Sina Hospital. After training in London, he pursued advanced fellowships in endourology and urologic oncology at USC. He has authored over 220 peer-reviewed articles and pioneered innovations such as a novel Foley catheter design for prostatectomy patients, filed with the U.S. Patent Office. His research encompasses surgical techniques, clinical trials, and outcomes analysis, particularly through the ROBUUST Collaborative Group. Key areas include nephroureterectomy protocols, robotic surgery efficacy, and the impact of preoperative factors on cancer outcomes. He also investigates disparities in cancer treatment and survival across populations. Dr. Djaladat’s clinical expertise spans robotic radical prostatectomy, cystectomy with urinary diversion, and management of testicular and bladder cancers. He actively contributes to surgical education, mentoring fellows in minimally invasive techniques and robotic surgery standards.
Dr. Wei Shen Tan, MD, PhD, FRCS, is an Assistant Professor of Urology at Yale School of Medicine, specializing in urologic oncology with expertise in bladder, prostate, and kidney cancers. He completed his Society of Urologic Oncology (SUO)-accredited fellowship at the University of Texas MD Anderson Cancer Center and a robotic urology fellowship at University College London Hospital. Dr. Tan is also an Honorary Associate Professor at University College London and a Fellow of the Royal College of Surgeons of England. Dr. Tan's research focuses on non-muscle-invasive bladder cancer (NMIBC), with particular interests in cancer diagnostics, novel treatments for bladder cancer, biomarker development, characterization of NMIBC, and optimizing perioperative outcomes through enhanced recovery protocols and robotic surgery. His work has resulted in over 100 peer-reviewed publications, with recent research emphasizing bladder-sparing therapies for BCG-unresponsive NMIBC, tumor stage impact on outcomes, and advancements in diagnosis and risk stratification. His publication trends show a strong focus on bladder cancer management, particularly BCG-unresponsive cases, with significant contributions to international guidelines and multi-institutional studies. Recent articles (2024-2025) predominantly address bladder-sparing therapies versus radical cystectomy, novel intravesical treatments, tumor staging implications, and international consensus recommendations for NMIBC management. Dr. Tan serves as a co-investigator in major clinical trials including DETECT I & II, HYMN, BOXIT, and HIVEC-II, and is on the editorial boards of the British Journal of Urology International and the Journal of Men's Health. His clinical approach emphasizes personalized care, minimally invasive robotic surgery when appropriate, and transparent communication with patients throughout their cancer journey.
Dr. Tim Smith is a Senior Lecturer at the School of Computer Science and Engineering, Bangor University. He holds an honorary position as Research Fellow at the University of Manchester until 2026. His primary research integrates computer science with medical applications, focusing on radiochemistry, radionuclide modelling, and radiobiology. His research interests include: Development of biomarkers for cancer therapy response prediction Radionuclide treatment mechanisms and modelling Tumor hypoxia detection and characterization Novel therapeutic approaches for bladder, prostate, and breast cancers CRISPR-Cas9 applications in oncology target identification Dr. Smith's recent publications (2021-2024) demonstrate a strong focus on translational oncology, with consistent themes in radionuclide therapy, hypoxia biomarkers, and molecular targeting. His work frequently utilizes advanced technologies including CRISPR screening, nanoparticle delivery systems, and multi-platform genomic analysis to address treatment resistance in urological and breast cancers. He actively contributes to academic service as an external examiner for postgraduate degrees and regularly delivers invited lectures on nuclear medicine topics. Dr. Smith is currently accepting PhD students for projects in radiochemistry, radionuclide modelling, and radiobiology.
Christopher A Warlick is a Professor and Head of the Department of Urology at the University of Minnesota Medical School. He is a leading expert in prostate and bladder cancer, with a strong focus on cancer screening, prevention, active surveillance, and novel therapeutic strategies including focal and immune-mediated treatments. Research Interests: Prostate Cancer Etiology and Survivorship Bladder Cancer Management Active Surveillance and Risk Stratification Minimally Invasive and Focal Therapies Transurethral Ablation Techniques Immunotherapy for Advanced Prostate Cancer His recent publications reflect a consistent and impactful research trajectory, emphasizing clinical trials, surgical outcomes, and innovative diagnostics. Themes include comparative effectiveness of robotic vs open surgery, microbiome implications in prostate cancer, and AI-driven therapeutic development. His work bridges clinical practice and translational research, with strong industry and multi-institutional collaborations. Scientific Awards and Recognition: No specific awards listed in the provided text. Advising and Grants: Dr. Warlick serves as Principal Investigator on multiple funded research projects, including a Phase II randomized trial (HEAT study), a multicenter ablation pilot, and an AI-designed mini-protein project funded by the U.S. Department of Defense. He collaborates with institutions such as Johns Hopkins University and industry partners including MacroGenics Inc., Francis Medical, Inc., and Photocure Inc. While formal student advisees are not listed, his role as PI indicates mentorship of junior researchers and clinical fellows. Labs and Research Teams: Dr. Warlick leads a multidisciplinary research team focused on urologic oncology, with active projects spanning from early detection to advanced therapeutics. His work is supported by a robust network of clinical collaborators, bioengineers, and data scientists, particularly in the areas of imaging, immunotherapy, and surgical innovation.
